An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Clinical trial NCT05239039 · COMPLETED
Trial details
- NCT number
- NCT05239039
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-15
- Primary completion
- 2023-07-17
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.